docosahexaenoic acid + arachidonic acid

This intervention is a research nutritional supplement consisting of a combination of two long-chain polyunsaturated fatty acids (LCPUFAs): docosahexaenoic acid (DHA), an omega-3 fatty acid, and arachidonic acid (AA), an omega-6 fatty acid. Studied primarily in the Omega Tots trial (NCT01576783) led by Dr. Sarah Keim, the intervention involves a daily oral dose of 200 mg DHA and 200 mg AA in a microencapsulated form. These fatty acids are essential structural components of neuronal and retinal cell membranes and are critical for normal brain development and neurological function. The supplementation was investigated for its potential to improve cognitive development, language, executive function, and behavioral outcomes in children born preterm (less than 35 weeks gestation). While the original trial did not show improvement in primary cognitive outcomes, follow-up studies have continued to evaluate the long-term developmental effects of toddlerhood supplementation into middle childhood.

Other names

docosahexaenoic acid + arachidonic acid-Sarah KeimDHA+AAOmega Tots intervention